RS Oncology
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1 Broadway Ste 14, Cambridge, Massachuse...Website
www.rsoncology.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About RS Oncology
RS Oncology is a clinical-stage biotech focused on developing innovative PRX3-targeting therapies to combat oxidative-stress-dependent cancers, including mesothelioma and metastatic diseases. The company aims to provide new treatment options for patients with aggressive cancers that have limited therapies available. Their team of experts is currently evaluating RSO-021 in a Phase 2 clinical trial for various cancer types, including metastatic breast and ovarian cancers. RS Oncology is dedicated to improving survival chances for patients and their families through novel scientific mechanisms.Explore more
RS Oncology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is RS Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
RS Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at RS Oncology
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once RS Oncology has new funding data
Click to see if RS Oncology had a recent Job posting/layoffs
Check if RS Oncology has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on RS Oncology recently announced quarterly report
Product Launch: Get notified when RS Oncology launches new products
Check out if RS Oncology is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to RS Oncology
Compare insights from companies similar to RS Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
RS Oncology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
RS Oncology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about RS Oncology.
RS Oncology Tech Stack
A closer look at the technologies used by RS Oncology
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Event
Events
Promotion
Executive Move
RS Oncology has announced that George Naumov has been promoted from Chief Head of Business Development, Operating Officer to the role of Chief Operations Officer & Chief Business Officer.
Promotion
Executive Move
RS Oncology News & Media
RS Oncology Data for Novel Treatment of Aggressive Cancers Selected for an Oral Presentation at ASCO Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #Lungcancer--RS Oncology, a clinical-stage biopharmaceutical company focused on developing novel treatments for aggressive and rare cancers, today announced that it will present the complete Phase 1 dose escalation data as an oral presentation at the world’s largest oncology meeting, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The MITOPE phase 1 multicenter study, (clinical trials.gov #NCT05278975) investigating the safety and tolerabRS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung
CAMBRIDGE, Mass. & LEICESTER, England--(BUSINESS WIRE)-- #Lungcancer--A first-in-kind therapy for pleural mesothelioma and metastatic disease to the lungs expanded into phase 2 of the UK investigational study.RS Oncology Announces New Preclinical Data Show RSO-021 May Block and/or Reverse the Progression of Aggressive Mesotheliomas, Improving Druggability
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #Lungcancer--RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, was part of a collaboration that recently shared new preclinical data at the IASLC 2023 World Conference on Lung Cancer in Singapore. The data, presented by Dr. Dean Fennell, represented a partnership between RS Oncology and other lead research institutions, including the University of Leicester and the Cunniff LaboratoRS Oncology Announces Completion of First-in-Human Phase 1 Clinical Trial of RSO-021, a Novel Irreversible Inhibitor of Mitochondrial PRX3
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #Lungcancer--RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, today announced the completion of the Phase 1 dose escalation portion of the MITOPE study (NCT05278975). The United Kingdom-based multicenter study met its primary objective of evaluating the safety and tolerability of RSO-021, a novel irreversible inhibitor of mitochondrial PRX3, in patients with malignant pleural meso
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding RS Oncology
Sign Up For FreeTo access detailed company insights
RS Oncology is a clinical-stage biotech focused on developing innovative PRX3-targeting therapies to combat oxidative-stress-dependent cancers, including mesothelioma and metastatic diseases. The company aims to provide new treatment options for patients with aggressive cancers that have limited therapies available. Their team of experts is current... Read More
